Myaware is the name for the Myasthenia Gravis Association. MGA has been around since May 1976. We support people with myasthenia and their families, increase public and medical awareness of the condition and raise funds for research and support staff as well as offering a benefits service.

If you’ve just been diagnosed with myasthenia, you’ve come to the right place. Our aim is to make your life easier. We provide information, advice and support. Call us now or join myaware, our online community. You will have free access to our resource centre which includes advice on everything from the latest medical developments and treatments to how to negotiate the benefits system. You can also get in touch with other members who understand what you are going through.

 

Ground-breaking research offers hope for people with myasthenia

 

Pioneering research into a debilitating muscle weakening disease is offering hope to people with myasthenia.

Myaware, the Myasthenia Gravis Association, is funding a new research project which will involve patients across the UK over the next four years.

Myasthenia gravis (MG) is a relatively rare disorder affecting the connection between nerves and muscles, causing muscle weakness which can affect mobility, speech, vision, the ability to swallow and even breathing.

In half of people diagnosed, the condition starts by just affecting the eyes, causing double vision and drooping eyelids but, over about two years, it often develops to affect other parts of the body.

The new research will look at why the disease develops from initial eye and vision problems into general MG in some patients but not others, so treatment can be tailored accordingly.

Ruth Ingledew, Chief Executive of Myaware, said: “Currently, there are no reliable tests or clinical evaluation features to help us determine which patients will develop generalisation of their myasthenia over time and may require more aggressive treatment.

“In this study, we intend to develop and validate robust clinical scores and blood tests in two large groups of MG patients that will enable us to predict which people who initially present with pure eye symptoms will develop generalised MG and which people won’t.

“By identifying those at risk of generalisation, we would hope that, in future, specific MG therapies can be tailored to the individual patient.”

Ruth added: “Myaware is very excited about this project and we are delighted to be able to fund this new research. It is of particular interest to many of our members who either have ocular MG or started with these symptoms before developing generalised MG.”

Dr Paul Maddison, Consultant Neurologist at Queen’s Medical Centre in Nottingham, and Dr Sui Wong, Consultant Neuro-opthalmologist at Moorfields Eye Hospital in London, are heading up the national research project.

Dr Wong will talk about the latest project at the Ocular Myasthenia Information Day in Birmingham on Friday, 26th June.

The event, organised by Myaware, will be held at the MacDonald Burlington Hotel, Burlington Arcade, New Street, from 12 noon to 4pm.

There will be talks, presentations and stalls providing information and advice for myasthenia patients and eye care professionals.

To find out more or book a place, email This email address is being protected from spambots. You need JavaScript enabled to view it. or call 01543 327438.

 

 

 

 

 

 

 

 

 

 

© 2015   Myasthenia Gravis Association

Donate